查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1718266

核酸药物市场按药物类型、分子类型、给药途径、治疗领域和最终用户划分－2025-2030 年全球预测

Nucleic Acid-Based Drugs Market by Drug Type, Molecule Type, Route of Administration, Therapeutic Area, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

核酸类药物市场规模预计2024年将达333.7亿美元，2025年将达377.6亿美元，2030年将达709.5亿美元，复合年增长率为13.39%。

主要市场统计数据
基准年2024年 333.7亿美元
预计2025年 377.6亿美元
预测年份 2030 709.5亿美元
复合年增长率（%） 13.39%

过去十年来，由于科学突破、创新临床策略以及对分子生物学的深入了解，核酸药物周围的环境发生了巨大变化。这个市场已经从一个小众研究领域转变为一个充满活力的行业，正在重新定义复杂疾病的治疗性介入。基因表现调控的开创性发现影响了各种类型药物的发现和开发，包括针对 RNA 和 DNA 功能的药物，提供了前所未有的治疗可能性。新颖的递送机制、增强的合成技术和强有力的监管支持的整合进一步确立了该领域作为未来治疗方法基石的地位。

生物技术与数位技术的日益融合不仅加速了研究，而且为快速的临床应用铺平了道路。学术界、製药公司和临床研究机构的相关人员正在利用这些发展来解决未满足的医疗需求。透过突破性科学和创新技术的结合，该市场有望显着改善患者的治疗效果和治疗的精确度。因此，核酸药物市场的持续发展反映出一个强大且有弹性的生态系统，能够在快速变化的全球医疗保健环境中克服挑战并抓住机会。

核酸药物市场的变革

近年来，核酸药物市场正在发生变革，重新定义治疗方法和市场动态。临床试验活动的激增凸显了精准医疗的重要性，使得早期化合物能够更快地通过临床流程。输送系统的突破性创新显着提高了核酸疗法的生物有效性和靶向功效，减轻了与稳定性和细胞摄取相关的传统挑战。

基因组编辑的进步，加上对 RNA 生物学的深入了解，为多功能、特异性患者的下一代治疗方法提供了框架。新的经营模式和协作框架促成了跨部门伙伴关係，学术界、研究界和工业界的领导者共用见解和资源。这种合作对于将候选药物纳入简化的监管途径并加速其进入市场至关重要。

这种转变的影响是深远的，不仅加速了市场成长，也刺激了推动技术创新的投资浪潮。透过增强的运算建模和尖端生物製造技术，相关人员现在可以在药物开发中享有更大的灵活性、设计精度和业务效率。市场中的这种变革性转变正在创造一种环境，在这种环境中，持续改进和突破性研究是长期成功的基础。

推动策略发展的关键环节分析

核酸药物市场的多面性透过多样化的细分策略凸显出来，这些策略为潜在趋势提供了关键见解。就药物类型而言，市场涵盖一系列治疗方式，包括反义寡核苷酸、DNA/RNA适体、基于mRNA的治疗剂、核苷类似物和RNA干扰（RNAi）治疗剂。我们对 RNAi 疗法进行了更深入的研究，将其分为微型RNA(MiRNA)、短髮夹 RNA (ShRNA) 和短干扰 RNA (SiRNA)。

此外，基于分子类型的细分将市场分为大分子和小分子，每个部分都表现出自己的市场动态和商业性潜力。按给药途径细分可提供对患者依从性和结果的宝贵见解，方式包括吸入和肌肉注射到静脉注射、口服和皮下注射，反映了患者需求和临床实践的复杂性。

在治疗领域方面，市场分析涵盖以下治疗领域：心血管疾病、感染疾病、代谢疾病、神经系统疾病、肿瘤学和罕见疾病。感染疾病分为感染疾病、感染疾病感染和病毒感染疾病，肿瘤分为骨髓恶性肿瘤和固态肿瘤。市场区隔评估对学术和研究机构、合约研究组织、医院和研究组织以及製药和生物技术公司的影响。这种细粒度的细分不仅为战略决策提供信息，而且还提供了有关患者人口统计、治疗方法类型和区域差异如何共同塑造市场轨蹟的详细视图。

目录

第一章 引言

第二章调查方法

第三章执行摘要

第四章 市场概述

第五章 市场洞察

  • 市场动态
    • 驱动程式
      • 遗传疾病和慢性疾病的发生率不断上升，推动了对核酸药物的需求。
      • 扩大政府投入，推动核酸药物生产
    • 限制因素
      • 核酸药物的製造和配方成本高昂
    • 机会
      • 透过生技公司之间的伙伴关係加强核酸药物
      • 开发下一代递送系统以提高核酸药物的生物有效性
    • 任务
      • 对核酸药物安全性和输送效率的担忧
  • 市场区隔分析
    • 药物类型：基于 mRNA 的疗法因其在疫苗开发中的变革性影响以及在重大健康危机期间的快速治疗反应而得到应用
    • 分子类型：小分子药物因其在製造、给药和成本效益方面的优势而被广泛采用。
    • 给药途径：肌肉注射因在疫苗研发中发挥重要作用而较为普遍。
    • 治疗领域：肿瘤核酸药物
    • 最终用户：由于需要先进的工具来解开基因调控和表达的复杂性，因此广泛应用于学术和研究实验室。
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社会
    • 技术的
    • 合法的
    • 环境

6. 核酸药物市场（依药物类型）

  • 反义寡核苷酸
  • DNA/RNA适体
  • 基于mRNA的疗法
  • 核苷类似物
  • RNA干扰（RNAi）疗法
    • 微型RNA（MiRNA）
    • 短髮夹RNA（ShRNA）
    • 小干扰RNA（SiRNA）

7. 核酸药物市场（依分子类型）

  • 大分子
  • 小分子

8. 核酸药物市场（依给药途径）

  • 吸入
  • 肌肉注射
  • 静脉
  • 口服
  • 皮下

9. 核酸药物市场（依治疗领域）

  • 心血管疾病
  • 感染疾病
    • 细菌感染疾病
    • 霉菌感染疾病
    • 病毒感染
  • 代谢紊乱
  • 神经系统疾病
  • 肿瘤学
    • 造血系统恶性肿瘤
    • 固态肿瘤
  • 罕见疾病

第 10 章核酸药物市场（依最终使用者）

  • 学术研究所
  • 合约研究组织
  • 医院和诊所
  • 製药和生物技术公司

11.美洲核酸药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

12. 亚太地区核酸药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

13. 欧洲、中东和非洲核酸药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十四章竞争格局

  • 2024年市场占有率分析
  • 2024年FPNV定位矩阵
  • 竞争情境分析
  • 战略分析与建议

公司名单

  • Alnylam Pharmaceuticals, Inc.
  • Amgen Inc.
  • Arcturus Therapeutics Holdings Inc.
  • Arrowhead Pharmaceuticals, Inc.
  • AstraZeneca PLC
  • Beam Therapeutics Inc.
  • Biogen, Inc.
  • BioMarin Pharmaceutical Inc.
  • BioNTech SE
  • Bluebird Bio, Inc.
  • CRISPR Therapeutics AG
  • CureVac NV
  • Dynavax Technologies Corporation
  • Editas Medicine, Inc.
  • Eli Lilly and Company
  • Evotec SE
  • F. Hoffmann-La Roche Ltd.
  • Generation Bio Co.
  • Gilead Sciences, Inc.
  • GSK PLC
  • Intellia Therapeutics, Inc.
  • Ionis Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Orna Therapeutics, Inc.
  • Pfizer Inc.
  • ProQR Therapeutics NV
  • Sangamo Therapeutics, Inc.
  • Sanofi SA
  • Sarepta Therapeutics, Inc.
  • Silence Therapeutics PLC
  • Stoke Therapeutics, Inc.
  • Takeda Pharmaceutical Company Limited
  • Vertex Pharmaceuticals Incorporated
  • Voyager Therapeutics, Inc.
  • Wave Life Sciences Ltd.
Product Code: MRR-CA7E340319CE

The Nucleic Acid-Based Drugs Market was valued at USD 33.37 billion in 2024 and is projected to grow to USD 37.76 billion in 2025, with a CAGR of 13.39%, reaching USD 70.95 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 33.37 billion
Estimated Year [2025] USD 37.76 billion
Forecast Year [2030] USD 70.95 billion
CAGR (%) 13.39%

The landscape of nucleic acid-based drugs has evolved substantially over the past decade, driven by significant scientific breakthroughs, innovative clinical strategies, and a deepening understanding of molecular biology. This market has transformed from a niche area of research to a dynamic field that is redefining therapeutic interventions for complex diseases. Pioneering discoveries in gene expression modulation have shaped the discovery and development of various drug types, such as those that target RNA and DNA functionality, leading to unprecedented therapeutic possibilities. The integration of novel delivery mechanisms, enhanced synthesis techniques, and robust regulatory support has further established this sector as a cornerstone for future medical treatments.

The ongoing convergence of biotechnology and digital advancements has not only accelerated research but has also paved the way for rapid clinical translations. Stakeholders across academia, pharmaceutical companies, and clinical research institutes are leveraging these developments to address unmet medical needs. This blend of breakthrough science and innovative technology positions the market to deliver substantial improvements in patient outcomes and therapeutic precision. As such, the ongoing evolution of the nucleic acid-based drugs market reflects a robust and resilient ecosystem capable of surmounting challenges and seizing opportunities in a rapidly changing global healthcare environment.

Transformative Shifts in the Nucleic Acid-Based Drugs Market

Recent years have witnessed transformative shifts in the nucleic acid-based drugs market that are redefining therapeutic modalities and market dynamics. A surge in clinical trial activity has underscored the importance of precision medicine, leading to early-stage compounds progressing more rapidly through clinical pipelines. Breakthrough innovations in delivery systems have significantly improved the bioavailability and targeting efficacy of nucleic acid therapeutics, thereby mitigating traditional challenges associated with stability and cellular uptake.

Advances in genomic editing, coupled with an enhanced understanding of RNA biology, have provided the framework for next-generation treatments that are both versatile and patient-specific. Emerging business models and collaborative frameworks have enabled cross-sector partnerships, where academia, research organizations, and industry leaders share insights and resources. This collaborative spirit has been essential in integrating novel drug candidates into streamlined regulatory pathways and expedited market accesses.

The impact of these shifts is far-reaching, inspiring a wave of investments that not only accelerate market growth but also foster technological innovation. With enhanced computational modeling and state-of-the-art biomanufacturing techniques, stakeholders now enjoy greater flexibility, design precision, and operational efficiency in drug development. The transformative shifts in this market are creating an environment where continuous improvement and breakthrough research are the foundations for long-term success.

Key Segmentation Insights Driving Strategy

The multifaceted nature of the nucleic acid-based drugs market is highlighted by a diverse segmentation strategy that provides critical insights into underlying trends. From a drug type perspective, the market encompasses an array of therapeutic modalities including Antisense Oligonucleotides, DNA/RNA Aptamers, mRNA-Based Therapeutics, Nucleoside Analogs, and RNA Interference (RNAi) Therapeutics. In particular, RNAi Therapeutics are examined in greater depth by further classifying the category into MicroRNA (MiRNA), Short Hairpin RNA (ShRNA), and Short Interfering RNA (SiRNA), each with distinctive mechanisms of action that pave the way for targeted therapy solutions.

In addition, the segmentation based on molecule type divides the market into Large Molecules and Small Molecules, with each segment demonstrating unique market dynamics and commercial potentials. The route of administration segmentation provides valuable insights into patient compliance and therapeutic outcomes, with modalities ranging from Inhalation and Intramuscular to Intravenous, Oral, and Subcutaneous methods that reflect the complexity of patient needs and clinical practices.

Examining therapeutic areas, the market is analyzed across Cardiovascular Diseases, Infectious Diseases, Metabolic Disorders, Neurological Disorders, Oncology, and Rare Diseases. Further refinement in this area sees the Infectious Diseases category dissected into Bacterial Infections, Fungal Infections, and Viral Infections, while Oncology is analyzed through the lens of Hematologic Malignancies and Solid Tumors. Complementing this, market end-user segmentation evaluates the impact on Academic & Research Institutes, Contract Research Organizations, Hospitals & Clinics, and Pharmaceutical & Biotechnology Companies. This intricate segmentation not only informs strategic decision-making, but also provides a granular view of how patient demographics, therapy types, and regional variations coalesce to shape market trajectory.

Based on Drug Type, market is studied across Antisense Oligonucleotides, DNA/RNA Aptamers, mRNA-Based Therapeutics, Nucleoside Analogs, and RNA Interference (RNAi) Therapeutics. The RNA Interference (RNAi) Therapeutics is further studied across MicroRNA (MiRNA), Short Hairpin RNA (ShRNA), and Short Interfering RNA (SiRNA).

Based on Molecule Type, market is studied across Large Molecule and Small Molecule.

Based on Route of Administration, market is studied across Inhalation, Intramuscular, Intravenous, Oral, and Subcutaneous.

Based on Therapeutic Area, market is studied across Cardiovascular Diseases, Infectious Diseases, Metabolic Disorders, Neurological Disorders, Oncology, and Rare Diseases. The Infectious Diseases is further studied across Bacterial Infections, Fungal Infections, and Viral Infections. The Oncology is further studied across Hematologic Malignancies and Solid Tumors.

Based on End-User, market is studied across Academic & Research Institutes, Contract Research Organizations, Hospitals & Clinics, and Pharmaceutical & Biotechnology Companies.

Global Regional Dynamics in Nucleic Acid-Based Drugs

Assessing the regional landscape of the nucleic acid-based drugs market provides a comprehensive perspective on global trends and regional variances. Market trends in the Americas continue to be driven by robust regulatory frameworks and extensive research infrastructure, attracting substantial investments and fostering innovation across both established markets and emerging clusters. Collaborative ecosystems with world-class research institutions and commercial players further strengthen market resilience.

In regions encompassing Europe, the Middle East & Africa, a blend of progressive regulatory reforms and increasing clinical trial activities is contributing to market expansion. This region is characterized by a harmonious blend of advanced research capabilities and strategic governmental incentives, thereby facilitating rapid clinical translations and enabling a smooth integration of breakthrough therapies into therapeutic regimens.

Meanwhile, in the Asia-Pacific region, rapid industrialization, rising healthcare demands, and a surge in technological advancements are collectively igniting market growth. Investments in infrastructure coupled with a rising focus on personalized medicine have catalyzed the development of state-of-the-art genome therapies. Each of these regions plays a significant role in influencing market strategies and expanding the global footprint of nucleic acid-based therapies, reflecting both localized opportunities and broader industry trends.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Strategic Company Performances and Market Leadership

In a rapidly advancing field marked by innovation and evolving therapeutic approaches, key companies have emerged as market leaders and principal drivers of growth. Prominent organizations such as Alnylam Pharmaceuticals, Inc., Amgen Inc., and Arcturus Therapeutics Holdings Inc. have spearheaded research initiatives that underscore the clinical potential of nucleic acid-based interventions. Moreover, companies like Arrowhead Pharmaceuticals, Inc. and AstraZeneca PLC have positioned themselves at the forefront of strategic collaborations and clinical advancements, further cementing their roles as industry pioneers.

The market is also notably influenced by dynamic contributions from Beam Therapeutics Inc. alongside acclaimed biopharmaceutical enterprises including Biogen, Inc. and BioMarin Pharmaceutical Inc. Furthermore, innovative players such as BioNTech SE and Bluebird Bio, Inc. are continually making strides through novel therapeutic platforms and breakthrough research. The involvement of CRISPR Therapeutics AG, CureVac N.V., and Dynavax Technologies Corporation underscores the commitment to harnessing genetic engineering techniques for therapeutic advancements.

Advancements spearheaded by Editas Medicine, Inc., Eli Lilly and Company, and Evotec SE have been pivotal in transforming market rifts into opportunities, while Generation Bio Co., Gilead Sciences, Inc., and GSK PLC continue to drive clinical research forward. With strategic insights from Intellia Therapeutics, Inc., Ionis Pharmaceuticals, Inc., and Merck & Co., Inc., along with innovative contributions by Moderna, Inc., Novartis AG, Novo Nordisk A/S, Orna Therapeutics, Inc., and Pfizer Inc., the competitive landscape remains both robust and dynamic. The involvement of additional influential organizations such as ProQR Therapeutics N.V., Sangamo Therapeutics, Inc., Sanofi SA, Sarepta Therapeutics, Inc., Silence Therapeutics PLC, Stoke Therapeutics, Inc., Takeda Pharmaceutical Company Limited, Vertex Pharmaceuticals Incorporated, Voyager Therapeutics, Inc., and Wave Life Sciences Ltd. further exemplifies the dynamic nature of this market and its potential for continued growth and innovation.

The report delves into recent significant developments in the Nucleic Acid-Based Drugs Market, highlighting leading vendors and their innovative profiles. These include Alnylam Pharmaceuticals, Inc., Amgen Inc., Arcturus Therapeutics Holdings Inc., Arrowhead Pharmaceuticals, Inc., AstraZeneca PLC, Beam Therapeutics Inc., Biogen, Inc., BioMarin Pharmaceutical Inc., BioNTech SE, Bluebird Bio, Inc., CRISPR Therapeutics AG, CureVac N.V., Dynavax Technologies Corporation, Editas Medicine, Inc., Eli Lilly and Company, Evotec SE, F. Hoffmann-La Roche Ltd., Generation Bio Co., Gilead Sciences, Inc., GSK PLC, Intellia Therapeutics, Inc., Ionis Pharmaceuticals, Inc., Merck & Co., Inc., Moderna, Inc., Novartis AG, Novo Nordisk A/S, Orna Therapeutics, Inc., Pfizer Inc., ProQR Therapeutics N.V., Sangamo Therapeutics, Inc., Sanofi SA, Sarepta Therapeutics, Inc., Silence Therapeutics PLC, Stoke Therapeutics, Inc., Takeda Pharmaceutical Company Limited, Vertex Pharmaceuticals Incorporated, Voyager Therapeutics, Inc., and Wave Life Sciences Ltd.. Actionable Strategies for Market Leadership Advancement

Industry leaders are presented with a range of actionable recommendations to navigate the complexities of the nucleic acid-based drugs market. Foremost, sustaining competitive advantage requires continuous investment in research and development, with a particular emphasis on next-generation sequencing and novel therapeutic platforms. Embracing collaborative research models will enable the pooling of expertise and resources, thereby accelerating the transition from lab-scale studies to clinical applications.

Market leaders should also focus on integrating real-world evidence and data analytics to better understand patient outcomes and refine therapeutic pipelines. Strengthening relationships with regulatory bodies and aligning with evolving global standards can expedite market entry and mitigate compliance risks. Tailored strategies that emphasize precision medicine should aim to capture patient-specific nuances while also addressing broader clinical needs.

Given the dynamic nature of market segmentation, organizations would benefit from a flexible portfolio strategy that is responsive to shifts across drug types, molecule classifications, administration routes, therapeutic areas, and end-user segments. Leveraging digital transformation tools and advanced biomanufacturing capacity will be essential in optimizing supply chains and fostering efficiency. This strategic approach can not only enhance market share but also secure long-term sustainability in the face of evolving global health challenges.

In-depth Conclusion on Market Trends and Strategies

The comprehensive analysis of the nucleic acid-based drugs market reveals a landscape defined by rapid innovation, evolving regulatory practices, and growing clinical potential. Transformations in scientific discovery and technological integration have laid the foundation for novel therapeutic solutions that address previously unmet healthcare needs. The intersection of scientific excellence and strategic market segmentation has provided stakeholders with a nuanced understanding of market dynamics, underscoring the importance of tailored strategies in both clinical and commercial domains.

This executive summary reflects a synthesis of critical insights ranging from transformative market shifts and segmentation insights to regional and corporate strategies that are collectively shaping the future of nucleic acid-based therapeutics. As scientific advancements continue to redefine therapeutic paradigms, industry players are well-advised to pursue collaborative frameworks, invest in groundbreaking research, and adapt to the evolving landscape with agility. The compelling integration of regional insights and strategic corporate insights further signifies the promising trajectory of this vibrant market, positioning it as a key driver of future success in global health innovation.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of genetic disorders and chronic diseases drives the need for nucleic acid-based drugs
      • 5.1.1.2. Increasing government investments to advance nucleic acid drug manufacturing
    • 5.1.2. Restraints
      • 5.1.2.1. High manufacturing and formulation costs associated with nucleic acid-based drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Partnership and collaboration among biotech companies to enhance nucleic acid-based drugs
      • 5.1.3.2. Developing next-generation delivery systems to improve the bioavailability of nucleic acid drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Safety and delivery efficacy concerns of nucleic acid-based drugs
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Drug Type: Usage of mRNA-based therapeutics due to transformative impact in vaccine development and rapid therapeutic responses during critical health crises
    • 5.2.2. Molecule Type: Widespread adoption of small molecule drugs due to their favorable properties in terms of manufacturing, administration, and cost-effectiveness
    • 5.2.3. Route of Administration: Prevalence of intramuscular injection due to its vital role in vaccine development
    • 5.2.4. Therapeutic Area: Utilization of nucleic acid-based drugs in oncology
    • 5.2.5. End-User: Widespread usage in academic & research institutes driven by need for advanced tools to unravel the intricacies of gene regulation and expression
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Nucleic Acid-Based Drugs Market, by Drug Type

  • 6.1. Introduction
  • 6.2. Antisense Oligonucleotides
  • 6.3. DNA/RNA Aptamers
  • 6.4. mRNA-Based Therapeutics
  • 6.5. Nucleoside Analogs
  • 6.6. RNA Interference (RNAi) Therapeutics
    • 6.6.1. MicroRNA (MiRNA)
    • 6.6.2. Short Hairpin RNA (ShRNA)
    • 6.6.3. Short Interfering RNA (SiRNA)

7. Nucleic Acid-Based Drugs Market, by Molecule Type

  • 7.1. Introduction
  • 7.2. Large Molecule
  • 7.3. Small Molecule

8. Nucleic Acid-Based Drugs Market, by Route of Administration

  • 8.1. Introduction
  • 8.2. Inhalation
  • 8.3. Intramuscular
  • 8.4. Intravenous
  • 8.5. Oral
  • 8.6. Subcutaneous

9. Nucleic Acid-Based Drugs Market, by Therapeutic Area

  • 9.1. Introduction
  • 9.2. Cardiovascular Diseases
  • 9.3. Infectious Diseases
    • 9.3.1. Bacterial Infections
    • 9.3.2. Fungal Infections
    • 9.3.3. Viral Infections
  • 9.4. Metabolic Disorders
  • 9.5. Neurological Disorders
  • 9.6. Oncology
    • 9.6.1. Hematologic Malignancies
    • 9.6.2. Solid Tumors
  • 9.7. Rare Diseases

10. Nucleic Acid-Based Drugs Market, by End-User

  • 10.1. Introduction
  • 10.2. Academic & Research Institutes
  • 10.3. Contract Research Organizations
  • 10.4. Hospitals & Clinics
  • 10.5. Pharmaceutical & Biotechnology Companies

11. Americas Nucleic Acid-Based Drugs Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Nucleic Acid-Based Drugs Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Nucleic Acid-Based Drugs Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2024
  • 14.2. FPNV Positioning Matrix, 2024
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. SCG Cell Therapy collaborates with A*STAR BTI and NATi to fast-track RNA-based cell and gene therapy in Singapore
    • 14.3.2. FDA approves TRYNGOLZA, fueling a pipeline for nucleic acid therapies
    • 14.3.3. Singapore launches non-GMP NATi mRNA BioFoundry to enhance automated nucleic acid therapeutics research
    • 14.3.4. City Therapeutics secures USD 135 million Series A financing to revolutionize RNA interference therapies and advance next-generation RNAi engineering platform
    • 14.3.5. Evonik partners with KNAUER to expands its portfolio of biosolution
    • 14.3.6. GSK deepens its focus on nucleic acid-based treatments through the acquisition of Elsie Biotechnologies
    • 14.3.7. Aldevron and Acuitas Therapeutics join forces to accelerate next-generation cell and gene therapies
    • 14.3.8. UK invests GBP 4.5 million in advanced nucleic acid drug manufacturing
    • 14.3.9. Asahi Kasei Bioprocess and Axolabs forge a strategic Berlin partnership to build a 59,000 square foot cGMP facility for scalable oligonucleotide therapeutic production
    • 14.3.10. Evonik signs a license with the University of Mainz to commercialize a new class of PEG lipids for nucleic acid delivery
  • 14.4. Strategy Analysis & Recommendation
    • 14.4.1. Pfizer Inc.
    • 14.4.2. Novo Nordisk A/S
    • 14.4.3. Moderna, Inc.
    • 14.4.4. Ionis Pharmaceuticals, Inc.

Companies Mentioned

  • 1. Alnylam Pharmaceuticals, Inc.
  • 2. Amgen Inc.
  • 3. Arcturus Therapeutics Holdings Inc.
  • 4. Arrowhead Pharmaceuticals, Inc.
  • 5. AstraZeneca PLC
  • 6. Beam Therapeutics Inc.
  • 7. Biogen, Inc.
  • 8. BioMarin Pharmaceutical Inc.
  • 9. BioNTech SE
  • 10. Bluebird Bio, Inc.
  • 11. CRISPR Therapeutics AG
  • 12. CureVac N.V.
  • 13. Dynavax Technologies Corporation
  • 14. Editas Medicine, Inc.
  • 15. Eli Lilly and Company
  • 16. Evotec SE
  • 17. F. Hoffmann-La Roche Ltd.
  • 18. Generation Bio Co.
  • 19. Gilead Sciences, Inc.
  • 20. GSK PLC
  • 21. Intellia Therapeutics, Inc.
  • 22. Ionis Pharmaceuticals, Inc.
  • 23. Merck & Co., Inc.
  • 24. Moderna, Inc.
  • 25. Novartis AG
  • 26. Novo Nordisk A/S
  • 27. Orna Therapeutics, Inc.
  • 28. Pfizer Inc.
  • 29. ProQR Therapeutics N.V.
  • 30. Sangamo Therapeutics, Inc.
  • 31. Sanofi SA
  • 32. Sarepta Therapeutics, Inc.
  • 33. Silence Therapeutics PLC
  • 34. Stoke Therapeutics, Inc.
  • 35. Takeda Pharmaceutical Company Limited
  • 36. Vertex Pharmaceuticals Incorporated
  • 37. Voyager Therapeutics, Inc.
  • 38. Wave Life Sciences Ltd.

LIST OF FIGURES

  • FIGURE 1. NUCLEIC ACID-BASED DRUGS MARKET MULTI-CURRENCY
  • FIGURE 2. NUCLEIC ACID-BASED DRUGS MARKET MULTI-LANGUAGE
  • FIGURE 3. NUCLEIC ACID-BASED DRUGS MARKET RESEARCH PROCESS
  • FIGURE 4. NUCLEIC ACID-BASED DRUGS MARKET SIZE, 2024 VS 2030
  • FIGURE 5. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2030 (%)
  • FIGURE 15. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
  • FIGURE 17. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 19. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. UNITED STATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 21. UNITED STATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 23. ASIA-PACIFIC NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 25. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 26. NUCLEIC ACID-BASED DRUGS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 27. NUCLEIC ACID-BASED DRUGS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. NUCLEIC ACID-BASED DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. NUCLEIC ACID-BASED DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DNA/RNA APTAMERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MRNA-BASED THERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEOSIDE ANALOGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MICRORNA (MIRNA), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SHORT HAIRPIN RNA (SHRNA), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SHORT INTERFERING RNA (SIRNA), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY LARGE MOLECULE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INHALATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY FUNGAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RARE DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 47. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 49. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 50. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 51. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 52. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 53. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 54. ARGENTINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. ARGENTINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 56. ARGENTINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. ARGENTINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 58. ARGENTINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 59. ARGENTINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 60. ARGENTINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 61. ARGENTINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 62. BRAZIL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. BRAZIL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 64. BRAZIL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. BRAZIL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 66. BRAZIL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 67. BRAZIL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 68. BRAZIL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 69. BRAZIL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 70. CANADA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. CANADA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 72. CANADA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. CANADA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 74. CANADA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 75. CANADA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 76. CANADA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 77. CANADA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 78. MEXICO NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. MEXICO NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 80. MEXICO NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. MEXICO NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 82. MEXICO NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 83. MEXICO NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 84. MEXICO NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 85. MEXICO NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 86. UNITED STATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. UNITED STATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 88. UNITED STATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. UNITED STATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 90. UNITED STATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 91. UNITED STATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 92. UNITED STATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 93. UNITED STATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 94. UNITED STATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 104. AUSTRALIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. AUSTRALIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 106. AUSTRALIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. AUSTRALIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 108. AUSTRALIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 109. AUSTRALIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 110. AUSTRALIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 111. AUSTRALIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 112. CHINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. CHINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 114. CHINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. CHINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 116. CHINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 117. CHINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 118. CHINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 119. CHINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 120. INDIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. INDIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 122. INDIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. INDIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 124. INDIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 125. INDIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 126. INDIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 127. INDIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 128. INDONESIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. INDONESIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 130. INDONESIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. INDONESIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 132. INDONESIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 133. INDONESIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 134. INDONESIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 135. INDONESIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 136. JAPAN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. JAPAN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 138. JAPAN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. JAPAN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 140. JAPAN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 141. JAPAN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 142. JAPAN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 143. JAPAN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 144. MALAYSIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. MALAYSIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 146. MALAYSIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. MALAYSIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 148. MALAYSIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 149. MALAYSIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 150. MALAYSIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 151. MALAYSIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 152. PHILIPPINES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. PHILIPPINES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 154. PHILIPPINES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. PHILIPPINES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 156. PHILIPPINES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 157. PHILIPPINES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 158. PHILIPPINES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 159. PHILIPPINES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 160. SINGAPORE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. SINGAPORE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 162. SINGAPORE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. SINGAPORE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 164. SINGAPORE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 165. SINGAPORE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 166. SINGAPORE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 167. SINGAPORE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH KOREA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. SOUTH KOREA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 170. SOUTH KOREA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. SOUTH KOREA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 172. SOUTH KOREA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 173. SOUTH KOREA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 174. SOUTH KOREA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 175. SOUTH KOREA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 176. TAIWAN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. TAIWAN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 178. TAIWAN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. TAIWAN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 180. TAIWAN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 181. TAIWAN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 182. TAIWAN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 183. TAIWAN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 184. THAILAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. THAILAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 186. THAILAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. THAILAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 188. THAILAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 189. THAILAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 190. THAILAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 191. THAILAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 192. VIETNAM NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 193. VIETNAM NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 194. VIETNAM NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 195. VIETNAM NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 196. VIETNAM NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 197. VIETNAM NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 198. VIETNAM NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 199. VIETNAM NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 209. DENMARK NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 210. DENMARK NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 211. DENMARK NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 212. DENMARK NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 213. DENMARK NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 214. DENMARK NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 215. DENMARK NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 216. DENMARK NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 217. EGYPT NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 218. EGYPT NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 219. EGYPT NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 220. EGYPT NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 221. EGYPT NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 222. EGYPT NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 223. EGYPT NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 224. EGYPT NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 225. FINLAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 226. FINLAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 227. FINLAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 228. FINLAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 229. FINLAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 230. FINLAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 231. FINLAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 232. FINLAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 233. FRANCE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 234. FRANCE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 235. FRANCE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 236. FRANCE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 237. FRANCE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 238. FRANCE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 239. FRANCE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 240. FRANCE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 241. GERMANY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 242. GERMANY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 243. GERMANY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 244. GERMANY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 245. GERMANY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 246. GERMANY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 247. GERMANY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 248. GERMANY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 249. ISRAEL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 250. ISRAEL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 251. ISRAEL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 252. ISRAEL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 253. ISRAEL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 254. ISRAEL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 255. ISRAEL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 256. ISRAEL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 257. ITALY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 258. ITALY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 259. ITALY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 260. ITALY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 261. ITALY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 262. ITALY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 263. ITALY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 264. ITALY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 265. NETHERLANDS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 266. NETHERLANDS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 267. NETHERLANDS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 268. NETHERLANDS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 269. NETHERLANDS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 270. NETHERLANDS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 271. NETHERLANDS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 272. NETHERLANDS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 273. NIGERIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 274. NIGERIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 275. NIGERIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 276. NIGERIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 277. NIGERIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 278. NIGERIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 279. NIGERIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 280. NIGERIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 281. NORWAY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 282. NORWAY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 283. NORWAY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 284. NORWAY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 285. NORWAY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 286. NORWAY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 287. NORWAY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 288. NORWAY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 289. POLAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 290. POLAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 291. POLAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 292. POLAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 293. POLAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 294. POLAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 295. POLAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 296. POLAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 297. QATAR NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 298. QATAR NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 299. QATAR NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 300. QATAR NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 301. QATAR NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 302. QATAR NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 303. QATAR NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 304. QATAR NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 305. RUSSIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 306. RUSSIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 307. RUSSIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 308. RUSSIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 309. RUSSIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 310. RUSSIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 311. RUSSIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 312. RUSSIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 313. SAUDI ARABIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 314. SAUDI ARABIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 315. SAUDI ARABIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 316. SAUDI ARABIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2